galmedpharma.com (GLMD) - Cash on Hand per Share

Galmed Pharmaceuticals Ltd. - graphic logo of issuer GLMD

The development of Galmed Pharmaceuticals (GLMD) depends on biological data rather than economic cycles. The free liquidity per share metric visualizes the dynamics of cash reserves, where the 10.91 level indicates the status of the parameter. The company's prospects rely on patents and Aramchol trials, although stringent FDA requirements limit the growth of the patient base within the fibrosis therapy ecosystem.

galmedpharma.com - GLMD Cash per Single Share (period 07/04/2022 - 09/10/2026)

Comprehensive metric breakdowns and analytics for galmedpharma.com (GLMD)

- cash availability and cash flow indicators:
Summary company analysis:GLMD, Galmed Pharmaceuticals Ltd
Manufactured products of Galmed Pharmaceuticals

Liquidity is critical for shielding biotech companies from market shocks. The financial cushion of Galmed Pharmaceuticals (GLMD) ensures the funding of clinical trials for Aramchol, a drug designed to combat liver fibrosis. This metric is calculated by dividing total cash reserves by the number of outstanding shares. By analyzing changes in cash per share, an investor assesses the intrinsic value of the security. The trend of this indicator determines the balance between financial stability and capital efficiency.